Pay in 4 interest-free payments of $28.98 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Studies indicate that ATP production is shifted towards glucose oxidation by Ranolazine
PubMed Central PMCID: PMC6003652
PubMed PMID: 12389628
InChiKey: RSAQARAFWMUYLL-UHFFFAOYSA-N
VX-661 Catalog No.:M10067-10 Studies indicate that ATP productionTezacaftor, also known asVX 661, is CFTR modulator. VX 661 is potentially useful for treatment of cystic fibrosis disease. Cystic fibrosis (CF) is a genetic disease caused by defects in the CF transmembrane regulator (CFTR) gene, which encodes an epithelial chloride channel. The most common mutation, 508CFTR, produces a protein that is misfolded and does not reach the cell membrane. VX 661 can correct trafficking of 508CFTR and partially restore